Beatriz Mothe

@irsicaixa.es

MD, PhD, Department of Infectious Diseases, Senior Investigator in Vaccines and Immunology
Fundació Lluita contra les Infeccions & IrsiCaixa, Hospital Germans Trias i Pujol

Beatriz Mothe


            Download Compact PDF  
https://researchid.co/beatriz.mothe

RESEARCH, TEACHING, or OTHER INTERESTS

Infectious Diseases, Immunology and Microbiology, Pharmacology (medical), Internal Medicine
4227

Scholar Citations

37

Scholar h-index

73

Scholar i10-index

RECENT SCHOLAR PUBLICATIONS

  • Humoral Immunogenicity of SARS-CoV-2 mRNA Primary Vaccination Among People with HIV
    DK Nomah, AG Robles, A Bruguera, JM Tiraboschi, S Benet, ...
    Microorganisms 14 (4), 893 , 2026
    2026
  • Method of treatment of hiv infection with vaccine
    C Brander, B MOTHE, I McGowan, Y ALARCÓN-SOTO
    US Patent App. 19/065,036 , 2026
    2026
  • Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial
    L Vandekerckhove, J Fox, B Mora-Peris, J Navarro, SD Allard, AJ Uriel, ...
    Nature Communications , 2026
    2026
    Citations: 3
  • PD-1 blockade enhances functional vaccine-induced HIV-1 CD8+ T-cell responses in PWH receiving early ART
    M Marin, A Ruiz, D Ouchi, E Jimenez-Moyano, R Peña, ...
    EBioMedicine 123 , 2026
    2026
    Citations: 2
  • Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trial
    JM Miro, F Torres, C Manzardo, E Bonfill, A Curran, P Domingo, ...
    Clinical Microbiology and Infection 32 (1), 169-176 , 2026
    2026
    Citations: 2
  • Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1. _
    L Bailón, Y Alarcón-Soto, JR Arribas, A Curran, A Llano, S Cedeño, ...
    Communications medicine , 2025
    2025
    Citations: 1
  • Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters
    N Pedreño-López, F Tarrés-Freixas, C Usai, D Raïch-Regué, S Benet, ...
    Communications Biology 8 (1), 1643 , 2025
    2025
    Citations: 1
  • Analytical treatment interruption as a tool in the evaluation of immune-mediated interventions for long-term antiretroviral-free control of HIV-1 among people with HIV
    AGP Dos Santos, M Abunimeh, B Mothe, JP Routy, JP Lalezari, ...
    Contemporary Clinical Trials, 108144 , 2025
    2025
    Citations: 1
  • Bictegravir/emtricitabine/tenofovir alafenamide for primary HIV infection: Efficacy, safety and impact on viral reservoir (the BIC-PHI clinical trial)
    J Ambrosioni, E de Lazzari, S Sánchez-Palomino, L Bailón, P Suanzes, ...
    Journal of Infection, 106651 , 2025
    2025
  • Resist to persist: resistance of the HIV reservoir to immune-mediated clearance
    TDT Nguyen, C Peligero-Cruz, B Mothe
    Current Opinion in HIV and AIDS 20 (6), 559-564 , 2025
    2025
    Citations: 1
  • Breakthrough mpox cases among different vaccination routes and under distinct HIV status
    S Benet, M Matilla, S Sabato, I Moraes-Cardoso, Y Alarcon-Soto, ...
    HIV MEDICINE 26, 100-101 , 2025
    2025
  • Dasatinib enhances innate macrophage restriction and limits HIV-1 replication
    C Sanchez Menendez, M Manzanares, A Simon Rueda, S Sabato, ...
    HIV MEDICINE 26, 223-224 , 2025
    2025
  • Dasatinib enhances NK cell cytotoxicity and reverses functional exhaustion in HIV infection
    MJ Munoz-Gomez, J Martinez-Laso, M Manzanares, ...
    HIV MEDICINE 26, 36-37 , 2025
    2025
  • Cellular and humoral response after mRNA SARS‐CoV‐2 vaccination in kidney transplant recipients living with HIV: A cross‐sectional study
    J Cacho, DK Nomah, N Egri, F Cofán, MÁ Marcos, MM Mosquera, ...
    HIV medicine 26 (10), 1562-1573 , 2025
    2025
  • Rapid clearance of inducible HIV-1 proviruses after initiation of antiretroviral therapy
    MC Puertas, L Bailón, V Urrea, MC García-Guerrero, Y Alarcón-Soto, ...
    PLoS pathogens 21 (9), e1013466 , 2025
    2025
    Citations: 3
  • Strategies to minimize time from HIV acquisition to ART initiation: the Barcelona Early-cART Program
    L Bailón, Y Alarcón-Soto, A Rivero, P Coll, J Saz, M Meulbroek, ...
    Open Forum Infectious Diseases 12 (9), ofaf545 , 2025
    2025
    Citations: 4
  • Prospects for therapeutic T-cell vaccine strategies for HIV cure
    B Mothe, C Brander
    Current Opinion in HIV and AIDS 20 (5), 463-471 , 2025
    2025
    Citations: 2
  • Lessons from the European mpox outbreak: strengthening cohort research for future pandemic preparedness
    A Visentin, A Nazeri, JL Peñalvo, A Gorska, RJ Davis, RL Flett, ...
    Clinical Microbiology and Infection , 2025
    2025
  • Interactions between gut microbiota, plasma metabolome and brain function in the setting of a HIV cure trial
    A Borgognone, A Prats, AA Sharma, I Martinez-Zalacaín, C Soriano-Mas, ...
    Frontiers in cellular and infection microbiology 15, 1629901 , 2025
    2025
    Citations: 1
  • Predictors of virological outcomes after analytical interruption of antiretroviral therapy following immune interventions with HTI vaccines in early-treated people with HIV: a …
    B Mothe, Y Alarcón-Soto, JR Arribas, A Curran, A Llano, S Cedeño, ...
    2025

MOST CITED SCHOLAR PUBLICATIONS

  • Gut microbiota linked to sexual preference and HIV infection
    M Noguera-Julian, M Rocafort, Y Guillén, J Rivera, M Casadellà, P Nowak, ...
    EBioMedicine 5, 135-146 , 2016
    2016
    Citations: 479
  • Definition of the viral targets of protective HIV-1-specific T cell responses
    B Mothe, A Llano, J Ibarrondo, M Daniels, C Miranda, J Zamarreño, ...
    Journal of translational medicine 9 (1), 208 , 2011
    2011
    Citations: 199
  • Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells
    E Pauls, A Ruiz, R Badia, M Permanyer, A Gubern, E Riveira-Muñoz, ...
    The Journal of Immunology 193 (4), 1988-1997 , 2014
    2014
    Citations: 175
  • High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control
    CT Berger, N Frahm, DA Price, B Mothe, M Ghebremichael, KL Hartman, ...
    Journal of virology 85 (18), 9334-9345 , 2011
    2011
    Citations: 173
  • CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control
    B Mothe, A Llano, J Ibarrondo, J Zamarreno, M Schiaulini, C Miranda, ...
    PloS one 7 (1), e29717 , 2012
    2012
    Citations: 169
  • A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques
    B Mothe, X Hu, A Llano, M Rosati, A Olvera, V Kulkarni, A Valentin, ...
    Journal of translational medicine 13 (1), 60 , 2015
    2015
    Citations: 121
  • Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection
    L Leal, AC Guardo, S Morón-López, M Salgado, B Mothe, C Heirman, ...
    Aids 32 (17), 2533-2545 , 2018
    2018
    Citations: 114
  • Efficacy, safety, and immunogenicity of a booster regimen of Ad26. COV2. S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled …
    K Hardt, A Vandebosch, J Sadoff, M Le Gars, C Truyers, D Lowson, ...
    The Lancet Infectious Diseases 22 (12), 1703-1715 , 2022
    2022
    Citations: 107
  • Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection
    Y Guillén, M Noguera-Julian, J Rivera, M Casadellà, AS Zevin, M Rocafort, ...
    Mucosal immunology 12 (1), 232-246 , 2019
    2019
    Citations: 100
  • HIVconsv vaccines and romidepsin in early-treated HIV-1-infected individuals: safety, immunogenicity and effect on the viral reservoir (Study BCN02)
    B Mothe, M Rosás-Umbert, P Coll, C Manzardo, MC Puertas, ...
    Frontiers in immunology 11, 823 , 2020
    2020
    Citations: 98
  • Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8 + T cell immunity
    M Rosás-Umbert, JD Gunst, MH Pahus, R Olesen, M Schleimann, ...
    Nature communications 13 (1), 6473 , 2022
    2022
    Citations: 90
  • Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1
    B Mothe, N Climent, M Plana, M Rosàs, JL Jiménez, ...
    Journal of Antimicrobial Chemotherapy 70 (6), 1833-1842 , 2015
    2015
    Citations: 83
  • Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial
    L Bailon, A Llano, S Cedeno, T Escriba, M Rosas-Umbert, M Parera, ...
    Nature medicine 28 (12), 2611-2621 , 2022
    2022
    Citations: 82
  • Therapeutic vaccination refocuses T-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study)
    B Mothe, C Manzardo, A Sanchez-Bernabeu, P Coll, S Morón-López, ...
    EClinicalMedicine 11, 65-80 , 2019
    2019
    Citations: 81
  • Defining the HLA class I‐associated viral antigen repertoire from HIV‐1‐infected human cells
    N Ternette, H Yang, T Partridge, A Llano, S Cedeño, R Fischer, ...
    European journal of immunology 46 (1), 60-69 , 2016
    2016
    Citations: 77
  • Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques
    V Kulkarni, A Valentin, M Rosati, C Alicea, AK Singh, R Jalah, ...
    PloS one 9 (1), e86254 , 2014
    2014
    Citations: 71
  • HIV-1 p24 gag Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice
    V Kulkarni, M Rosati, A Valentin, B Ganneru, AK Singh, J Yan, M Rolland, ...
    PloS one 8 (3), e60245 , 2013
    2013
    Citations: 69
  • Novel approaches towards a functional cure of HIV/AIDS
    L Bailon, B Mothe, L Berman, C Brander
    Drugs 80 (9), 859 , 2020
    2020
    Citations: 68
  • Gut microbiome signatures linked to HIV-1 reservoir size and viremia control
    A Borgognone, M Noguera-Julian, B Oriol, L Noël-Romas, M Ruiz-Riol, ...
    Microbiome 10 (1), 59 , 2022
    2022
    Citations: 66
  • Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 …
    JD Gunst, J Gohil, JZ Li, RJ Bosch, A White, Catherine Seamon, TW Chun, ...
    Nature communications 16 (1), 906 , 2025
    2025
    Citations: 63